

No significant differences in BioGaia's diabetes study

In 2012 BioGaia initiated a double-blind, placebo-controlled study to investigate the effects of *Lactobacillus reuteri* Protectis on blood glucose in type 2 diabetics. Despite positive results from an earlier pilot study no significant differences between the groups were seen in this study.

Forty-five patients with type 2 diabetes were included in the 12-week long study. The analysis of the results will continue to capitalise on as much knowledge as possible.

"There is information in the study that makes us want to go further and analyse if a change in some of the essential parameters in the study or in the study design may be a possible approach for a solution", says Per-Anders Jansson, Associate Professor and Medical Advisor at Gothia Forum, Sahlgrenska University Hospital, Gothenburg.

"Unfortunately we did not see any significant differences between the groups, but given the positive pilot study and the lessons we can draw from the recently completed study, we intend to continue our work to, with the help of a change of the microbiome, achieve improvements for patients with type 2 diabetes", says Peter Rothschild, President BioGaia.

In the 12-week study 45 patients with type 2 diabetes were included. The study was conducted together with Gothia Forum for Clinical Research at the Sahlgrenska University Hospital in Gothenburg in collaboration with Sahlgrenska Center for Cardiovascular and Metabolic Research.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2014-01-14 It's possible to prevent colic in healthy infants
2013-12-05 One of the world's most widespread infections – BioGaia's Gastrus improves treatment
2013-11-15 BioGaia signs exclusive agreement for drops and tablets in Brazil

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 28 January 2014, 3:00 pm CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com